Eli Lilly’s Once-Weekly Insulin Shows Promise in Phase III Diabetes Trials
Exciting Developments in Diabetes Treatment
Eli Lilly recently presented compelling findings regarding its once-weekly insulin efsitora at the 2024 Annual Meeting of the European Association for the Study of Diabetes. These findings stem from two Phase III trials, QWINT-2 and QWINT-5, which demonstrate that efsitora holds its ground against daily insulin options for Type 1 and Type 2 diabetes patients.
QWINT-2 Trial Insights
- Efsitora resulted in a 1.34% reduction in A1C for Type 2 diabetes patients, closely comparable to the 1.26% reduction seen with daily insulin degludec.
- Patients using efsitora exhibited better time in range, enjoying an additional 45 minutes daily compared to their degludec counterparts.
- Safety profiles indicated efsitora had similar instances of severe hypoglycemic episodes.
Further Evidence from QWINT-5
- In the QWINT-5 trial, efsitora matched daily degludec injections with approximately equal A1C reductions after 26 weeks.
- Patients reported similar durations of hypoglycemia, though efsitora had a slightly higher rate of severe events.
Lilly’s breakthroughs in insulin treatment may shift diabetes management, offering patients a streamlined alternative to daily injections.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.